Early vascular responses to abluminal biodegradable polymer-coated versus circumferential durable polymer-coated newer-generation drug-eluting stents in humans: a pathological study.


Journal

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040

Informations de publication

Date de publication:
20 Mar 2023
Historique:
pubmed: 1 12 2022
medline: 22 3 2023
entrez: 30 11 2022
Statut: ppublish

Résumé

Recent clinical studies are testing strategies for short (1-3 months) dual antiplatelet therapy following newer-generation drug-eluting stent (DES) placement. However, detailed biological responses to newer-generation DES remain unknown in humans. We sought to evaluate early pathologic responses to abluminal biodegradable polymer-coated (BP-) DES compared with circumferential durable polymer-coated (DP-) DES in human autopsy cases. The study included 38 coronary lesions with newer-generation DES implanted for <90 days (DP-DES=24, BP-DES=14) in 26 autopsy cases. The degree of strut coverage was defined as follows: grade 0 (bare), grade 1 (with fibrin or tissues/cells without endothelium), grade 2 (with single-layered endothelium), and grade 3 (with endothelium and underlying smooth muscle cell layers).  The duration following implantation was similar in DP- and BP-DES (median=20 vs 17 days). A total of 2,022 struts (DP-DES=1,297, BP-DES=725) were pathologically analysed. Focal grade 2 coverage was observed as early as 5 days after the implantation in both stents. The multilevel mixed-effects ordered logistic regression model demonstrated that BP-DES exhibited greater strut coverage compared with DP-DES (odds ratio [OR]: 3.64, 95% confidence interval [CI]: 1.37-9.67; p=0.009), which remained significant after adjustment for the duration following implantation and underlying tissue characteristics (OR: 2.74, 95% CI: 1.10-6.80; p=0.030). The predictive probability of grade 2 and 3 coverage was comparably limited at 30 days (DP-DES=17.1%, BP-DES=28.7%) and increased at 90 days (DP-DES=76.5%, BP-DES=86.6%). Both stents showed low inflammation and a similar degree of fibrin deposition. Single-layered endothelial coverage begins in the days after newer-generation DES placement, and BP-DES potentially exhibit faster strut coverage with smooth muscle cell infiltration than DP-DES in humans. Nevertheless, vessel healing remains suboptimal in both stents at 30 days.

Sections du résumé

BACKGROUND BACKGROUND
Recent clinical studies are testing strategies for short (1-3 months) dual antiplatelet therapy following newer-generation drug-eluting stent (DES) placement. However, detailed biological responses to newer-generation DES remain unknown in humans.
AIMS OBJECTIVE
We sought to evaluate early pathologic responses to abluminal biodegradable polymer-coated (BP-) DES compared with circumferential durable polymer-coated (DP-) DES in human autopsy cases.
METHODS METHODS
The study included 38 coronary lesions with newer-generation DES implanted for <90 days (DP-DES=24, BP-DES=14) in 26 autopsy cases. The degree of strut coverage was defined as follows: grade 0 (bare), grade 1 (with fibrin or tissues/cells without endothelium), grade 2 (with single-layered endothelium), and grade 3 (with endothelium and underlying smooth muscle cell layers).
RESULTS RESULTS
 The duration following implantation was similar in DP- and BP-DES (median=20 vs 17 days). A total of 2,022 struts (DP-DES=1,297, BP-DES=725) were pathologically analysed. Focal grade 2 coverage was observed as early as 5 days after the implantation in both stents. The multilevel mixed-effects ordered logistic regression model demonstrated that BP-DES exhibited greater strut coverage compared with DP-DES (odds ratio [OR]: 3.64, 95% confidence interval [CI]: 1.37-9.67; p=0.009), which remained significant after adjustment for the duration following implantation and underlying tissue characteristics (OR: 2.74, 95% CI: 1.10-6.80; p=0.030). The predictive probability of grade 2 and 3 coverage was comparably limited at 30 days (DP-DES=17.1%, BP-DES=28.7%) and increased at 90 days (DP-DES=76.5%, BP-DES=86.6%). Both stents showed low inflammation and a similar degree of fibrin deposition.
CONCLUSIONS CONCLUSIONS
Single-layered endothelial coverage begins in the days after newer-generation DES placement, and BP-DES potentially exhibit faster strut coverage with smooth muscle cell infiltration than DP-DES in humans. Nevertheless, vessel healing remains suboptimal in both stents at 30 days.

Identifiants

pubmed: 36448921
pii: EIJ-D-22-00650
doi: 10.4244/EIJ-D-22-00650
pmc: PMC10018292
pii:
doi:

Substances chimiques

Polymers 0
Fibrin 9001-31-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1284-1294

Références

Int J Cardiol. 2021 Sep 1;338:42-49
pubmed: 34174338
N Engl J Med. 2019 Nov 21;381(21):2032-2042
pubmed: 31556978
Circ J. 2018 Sep 25;82(10):2594-2601
pubmed: 29998921
J Long Term Eff Med Implants. 2000;10(1-2):143-51
pubmed: 10947627
Nat Rev Cardiol. 2012 May 22;9(8):439-53
pubmed: 22614618
Nat Rev Cardiol. 2020 Jan;17(1):37-51
pubmed: 31346257
Cardiovasc Interv Ther. 2019 Jan;34(1):14-24
pubmed: 29318464
Circ Cardiovasc Interv. 2020 May;13(5):e008869
pubmed: 32338525
JACC Cardiovasc Interv. 2017 Dec 11;10(23):2375-2387
pubmed: 29102583
Lancet. 2018 Mar 31;391(10127):1274-1284
pubmed: 29544699
JACC Cardiovasc Interv. 2015 Aug 17;8(9):1248-1260
pubmed: 26292590
Circulation. 2001 Jul 24;104(4):473-9
pubmed: 11468212
JAMA Cardiol. 2022 Apr 01;7(4):407-417
pubmed: 35234821
Circulation. 2007 May 8;115(18):2435-41
pubmed: 17438147
N Engl J Med. 2021 Oct 28;385(18):1643-1655
pubmed: 34449185
Nat Rev Cardiol. 2016 Feb;13(2):79-98
pubmed: 26503410
J Am Heart Assoc. 2016 Oct 19;5(10):
pubmed: 27792651
Heart. 2003 Feb;89(2):133-8
pubmed: 12527658
Circulation. 2014 Jan 14;129(2):211-23
pubmed: 24163064
JAMA. 2019 Jun 25;321(24):2414-2427
pubmed: 31237644

Auteurs

Yasuhito Kawagoe (Y)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Department of Advanced Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Fumiyuki Otsuka (F)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Daisuke Onozuka (D)

Department of Medical Informatics and Clinical Epidemiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Hatsue Ishibashi-Ueda (H)

Department of Pathology, National Cerebral and Cardiovascular Center, Suita, Japan.

Yoshihiko Ikeda (Y)

Department of Pathology, National Cerebral and Cardiovascular Center, Suita, Japan.

Keiko Ohta-Ogo (K)

Department of Pathology, National Cerebral and Cardiovascular Center, Suita, Japan.

Manabu Matsumoto (M)

Department of Pathology, National Cerebral and Cardiovascular Center, Suita, Japan.

Kisaki Amemiya (K)

Department of Pathology, National Cerebral and Cardiovascular Center, Suita, Japan.

Yasuhide Asaumi (Y)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Yu Kataoka (Y)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Kunihiro Nishimura (K)

Department of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan.

Yoshihiro Miyamoto (Y)

Department of Advanced Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Open Innovation Center, National Cerebral and Cardiovascular Center, Suita, Japan.

Teruo Noguchi (T)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Aloke V Finn (AV)

CVPath Institute, Inc., Gaithersburg, MD, USA.

Renu Virmani (R)

CVPath Institute, Inc., Gaithersburg, MD, USA.

Kinta Hatakeyama (K)

Department of Pathology, National Cerebral and Cardiovascular Center, Suita, Japan.

Satoshi Yasuda (S)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Department of Advanced Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH